The AMNOG law redifines the rules for market access. This especially impacts the price setting for new and also established pharmaceutical products. The free pricing policy that existed in the past is replaced by a Government fixed pricing system. If you can not prove additional benefits, your product price will be fixed or you will receive a price based on a comparative existing therapy.
We accompany you and manage the whole price-finding process for both current and new products. This process presents a sifnificant challenge in any case. We will lead you though the maze of requirements which must be met in order to put together an excellent medical benefit dossier that takes your business case into account.